STA-013

• Description :

  STA-013 is a EphB tyrosine kinase inhibitor. STA-013 shows promising potency against EphB1 (IC50 = 0.69 µM), EphB2 (IC50 = 1.73 µM), and EphB4 (IC50 = 1.02 µM) tyrosine kinases. STA-013 results a inhibition of the EphB phosphorylated signal, coupled with increased p-AKT/AKT signaling, to suggest insulin signaling activation. STA-013 inhibits EphB tyrosine kinase by enhancing insulin receptor beta (IRβ) signaling, and decreasing TGF-β levels in the heart. STA-013 can be used for the study of type 2 diabetes and cardiac complications (diabetic cardiomyopathy) [1].

• UNSPSC :

  12352005

• Target :

  Akt; EGFR; Mitochondrial Metabolism

• Related Pathways :

  JAK/STAT Signaling; Metabolic Enzyme/Protease; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK

• Applications :

  Metabolism-sugar/lipid metabolism

• Field of Research :

  Metabolic Disease

• Smiles :

  O=C(NCC1=CC=CC2=C1C=CN2C(C3=CC=CC=C3)=O)C4=CC5=CC=CN=C5S4

• Molecular Formula :

  C24H17N3O2S

• Molecular Weight :

  411.48

• References & Citations :

  [1]Tareq S, et al. Discovery of pan-EphB tyrosine kinase inhibitor for metabolic syndrome sparing EphB3 signaling in mice. Pharmacol Res. 2025 Sep;219:107900.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  EGFR/ErbB1/HER1; ErbB2/HER2; ErbB4/HER4